Bristol Myers Squibb (BMY): Opdivo/Yervoy (chemo-free) regimen shows...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	827
Posts	119492
Boards Moderated	15
Alias Born	09/05/2002

DewDiligence

Re: None

Thursday, 02/14/2019 4:46:27 PM

Thursday, February 14, 2019 4:46:27 PM

Opdivo/Yervoy (chemo-free) regimen shows early promise in mCRPC:

https://finance.yahoo.com/news/opdivo-nivolumab-plus-yervoy-ipilimumab-210000075.html

Bristol-Myers Squibb Company today announced data evaluating Opdivo (nivolumab) in combination with Yervoy (ipilimumab) in patients with metastatic castration-resistant prostate cancer (mCRPC). Results from an interim analysis of the Phase 2 CheckMate-650 trial showed that among 32 asymptomatic or minimally symptomatic patients whose disease had progressed after second-generation hormone therapy and who had not received chemotherapy (cohort 1), with a median follow-up of 11.9 months, the objective response rate (ORR) was 25%.

Additionally, among 30 patients whose disease progressed after taxane-based chemotherapy (cohort 2), with a median follow-up of 13.5 months, the ORR was 10%.

Across both cohorts, higher response rates were seen in certain patient sub-groups, including patients with high (above median) tumor mutational burden and patients with homologous recombination deficiency.

There is no control arm in this study.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”